AC
VRTX icon

Asio Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Asio Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,128
Closed -$5.18M – 111
2024
Q3 		$5.18M Sell
11,128
-33
-0.3% -$15.9K 0.98% 34
2024
Q2 		$5.23M Buy
11,161
+236
+2% +$102K 1.07% 29
2024
Q1 		$4.57M Sell
10,925
-19
-0.2% -$8.03K 0.97% 41
2023
Q4 		$4.45M Sell
10,944
-810
-7% -$299K 1.04% 34
2023
Q3 		$4.09M Sell
11,754
-95
-0.8% -$33.2K 1.09% 31
2023
Q2 		$4.17M Sell
11,849
-99
-0.8% -$33.4K 1.02% 32
2023
Q1 		$3.76M Sell
11,948
-37
-0.3% -$11.1K 0.98% 36
2022
Q4 		$3.46M Sell
11,985
-76
-0.6% -$23.2K 1% 38
2022
Q3 		$3.49M Buy
12,061
+468
+4% +$135K 1.11% 32
2022
Q2 		$3.27M Buy
11,593
+347
+3% +$92.9K 1.03% 30
2022
Q1 		$2.94M Buy
+11,246
New +$2.67M 0.83% 50

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Asio Capital's VRTX Position: Q4 2024 in Review

Asio Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 11,128 shares — an estimated $5.18M sold.

Asio Capital first reported a position in VRTX in Q1 2022 and held it in 11 quarters. The position peaked at $5.23M in Q2 2024. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Asio Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Asio Capital sold 11,128 Vertex Pharmaceuticals shares in Q4 2024, an estimated $5.18M.
  • Asio Capital first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Asio Capital's Vertex Pharmaceuticals position peaked at $5.23M in Q2 2024.
  • 1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Asio Capital's 13F filing for Q4 2024, filed 21 Jan 2025.